Biotechnology News

SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company targeting RAS-mutated cancer by leveraging PLK1 inhibition, today announced...

Arcutis today announced that management will present at the Guggenheim investor conference, taking place November 9-11, 2026, in Boston.

COMMUNIQUÉ DU 27 OCTOBRE 2026 RELATIF AU DÉPÔT DU PROJET DE NOTE D’INFORMATION ÉTABLI PAR LA SOCIÉTÉ EUROBIO SCIENTIFIC EN RÉPONSE AU PROJET D’OFFRE PUBLIQUE DE RETRAIT SUIVIE D’UN RETRAIT...

COMMUNIQUÉ DU 27 OCTOBRE 2026 RELATIF AU DÉPÔT D’UNE OFFRE PUBLIQUE DE RETRAIT SUIVIE D’UN RETRAIT OBLIGATOIREVISANT LES ACTIONS DE LA SOCIÉTÉ EUROBIO SCIENTIFIC Pièce jointe ...

– Results demonstrate consistent improvements across measures of disease activity, quality of life, and pharmacodynamic markers, with a tolerable safety profile across all afimetoran dose groups – –...

Addition continues to progress a novel pipeline of non-viral, LNP-delivered, RNA-only gene-addition therapies for severe, lifelong genetic and non-genetic diseasesCompany to present an oral...

Bavarian Nordic donates 75,000 doses of MVA-BN® and will also supply 150,000 doses to new global mpox vaccine emergency stockpile.

Bavarian Nordic donerer 75.000 doser MVA-BN® og vil desuden levere 150.000 doser til det nye globale nødberedskabslager for mpox-vacciner.Beredskabslageret er en vigtig milepæl i det globale beredskab...

REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming...

50% of patients who achieved a complete response (n=6) remain disease-free more than two years after treatment80% of patients treated with SYNC-T Therapy SV-102 (n=15) alive at 24 months Median...